Navigation Links
Company stock prices before public announcements of oncology trial results

Prior knowledge of phase III clinical trials of new drugs and Food and Drug Administration (FDA) regulatory decisions may affect the price of a drug company's stock according to a study published September 26 in the Journal of the National Cancer Institute.

Regulatory decisions made by the FDA and phase III clinical trials are important for the financial success of new drugs. Investors with information on the trial results and FDA decisions before they are released to the public may profit regardless of the drug's success or failure. This information can also influence the market value of the companies that bring the drugs to market. Trial investigators, company employees, and outside consultants are aware of trials results before they are made public, and investment analysts may go to great lengths to obtain this "insider information" for their clients because the results are not necessarily reflected in the market price of a stock.

To determine what kind of impact prior knowledge of clinical results may have had on a company's market value and stock prices of particular drugs, Allan S. Detsky, M.D., Ph.D., and colleagues did a retrospective analysis of stock prices of publicly traded biotechnology and pharmaceutical companies before and after key public announcements made between January 2000 and January 2009 regarding 23 positive and 36 negative phase III clinical trials in which their cancer drug was tested and from 41 positive and nine negative FDA regulatory decisions. They obtained stock prices from the Center for Research in Security Prices and Bloomberg Professional. The researchers then analyzed each company's daily closing stock price before and after the date of a public announcement.

The researchers found that the average stock price of a drug 120 days before a phase III clinical trial announcement showed an increase of 13.7% for companies that reported positive trials and a decrease of 0.7% percent for companies that reported negative trials. In a post hoc analysis that compared average stock prices over the period from 120 to 60 days before clinical trial announcements to the average price for the subsequent 60 days, companies reporting positive trial results saw a mean increase in their stock price of 9.4%, while those reporting negative trial results saw a decrease of 4.5% in their stock price, a statistically significant difference. Company stock prices before FDA regulatory decisions, however, didn't differ between companies with positive and negative decisions.

According to the researchers, one possible explanation for these trends is insider trading, where individuals make stock trades based on nonpublic information or by providing nonpublic information to others. The researchers write, "The changes in post-announcement share price that we have demonstrated highlight the potential use of this information by individuals for profit once it becomes public." They add that FDA decisions would not influence stock prices because the information on which they are based is already public. However, the researchers also point out certain limitations of the study, including selection bias, the fact that it was retrospective, and the small number of companies included in the analysis. They also note differences in the companies, namely that those reporting positive phase III study results are likely to be more established and profitable.

Even so, the researchers say they were surprised to see the differences in company stock prices in relation to positive and negative trials, given all the variables affecting a company's stock price. They write, "The results of this study call for increased awareness by investigators regarding the legal and ethical aspects of divulging nonpublic information regarding clinical trials."

In an accompanying editorial, Adam Feuerstein, a Senior Columnist at TheStreet, and Mark J. Ratain, M.D., of the University of Chicago, write that the suggestion by Dr. Detsky and colleagues that some investigators involved in phase III trials are illegally tipping the results, which is a criminal violation of the Securities Exchange Act, is "of grave concern."

However, the editorialists also maintain that the positive and negative trials were different in other ways. In undertaking their own analysis of the companies studied, they calculated the market capitalization of the companies at 120 days before public announcements. They found that it was 80-fold greater for companies with positive trials compared to those with negative trials, implying that the subsequent negative trials were not a surprise. They write, "The perceived high risk of failure of phase III oncology trials is primarily limited to smaller oncology companies." Furthermore, "The stock market is known to anticipate future events, as opposed to reacting to the past. Thus, it is not surprising that sophisticated investors are able to judge the probability of success, which is reflected in the share price."


Contact: Zack Rathner
Journal of the National Cancer Institute

Related medicine news :

1. Bullying May Accompany Drive to Be Popular
2. How One Company Fought the Flu
3. Avandia Heart Risks Buried by Drug Company: Report
4. Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times
5. Los Angeles Pool Service Company Pool Joe is Going Organic using Eco-Safe Pool Products
6. SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
7. MISI Company, Ltd. Acquires Cue Data Services and Expands Geographically to New England and Canada
8. United Staes Company, First Defense Nasal Screens Signs Multi-Million Dollar Exclusive Distributorship Contract with U.A.E Company.
9. High Customer Retention and Continual Product Demand Drive Steady Growth for Innovative Healthcare Company
10. MedTouch Launches Revitalized Website for Sterling Life Insurance Company
11. Endeavor Telecom Introduces Upgraded Company Health Initiative to Encourage Healthy Lifestyle Choices
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: